Concinnity Genetics was founded by Dr. Jessica Birt and Dr. Matt Dale of the UK Centre for Mammalian Synthetic Biology in SynthSys and aims to improve the safety and efficacy of gene therapies using AI. Concinnity Genetics develops gene control systems that act like a switch for gene therapies, turning them off when they are active in the wrong cells to prevent side effects from occurring. The algorithm is based on unique AI technology developed by Jessica Birt as part of her PhD at the UK Centre for Mammalian Synthetic Biology in Professor Susan Rosser's lab, and is able to rapidly improve and learn from previous designs. Concinnity Genetics journey Conncinnity genetics was selected to participate in the Crick Institute's KQ Labs acceleration programme (including £40,000 in corporate funding). On the same day in 2021, the team presented as a finalist on the virtual stage of Conception X Demo Day. Conception X is a nine month venture programme that helps PhD students launch deep tech startups based on their research. As part of their startup programme, they have now received £270,000 from Scottish Enterprise and have access to key lab space. Conncinnity Genetics Goals: Build their own data set within a year Develop five new gene control systems over the next 18 months Eventually build a comprehensive portfolio of modular control systems to be tested internally Growing market Concinnity Gentics is well positioned to serve the growing gene editing and mRNA therapeutics market. The company is part of a dynamic local ecosystem that will support future mammalian engineering biology. Related Links Centre for Synthetic and Systems Biology Concinnity Genetics - site under development UK Centre for Mammalian Synthetic Biology KQ labs – Crick Institute Conception x This article was published on 2022-11-03
